Biomarkers /

SETD7

Back to Biomarkers List

Overview

Location [1]
4q31.1
Protein [2]
Histone-lysine N-methyltransferase SETD7
Synonyms [1]
SET7/9, SET9, SET7, KMT7

SETD7 is altered in 0.19% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, follicular lymphoma, B-cell lymphoblastic leukemia/lymphoma, mantle cell lymphoma, and T-cell lymphoblastic leukemia/lymphoma having the greatest prevalence of alterations [3].

SETD7 GENIE Cases - Top Diseases

The most common alterations in SETD7 are SETD7 Amplification (0.07%), SETD7 Mutation (0.07%), SETD7 Loss (0.05%), SETD7 T75S (0.05%), and SETD7 D88H (0.02%) [3].

SETD7 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.